# Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

> **NCT01411696** · — · COMPLETED · sponsor: **Allergan** · enrollment: 289 (actual)

## Conditions studied

- Retinal Vein Occlusion
- Macular Edema

## Interventions

- **DRUG:** dexamethasone intravitreal implant 0.7 mg

## Key facts

- **NCT ID:** NCT01411696
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2013-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01411696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01411696, "Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01411696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*